Lupin to develop Brazil as Latin American manufacturing, export hub

Most neighbouring countries recognise the Brazilian drug regulator's approvals

Lupin, the pharmaceuticals major, plans to develop its Brazilian operations into a manufacturing hub for the Latin American region. Most neighbouring countries there recognise the Brazilian drug regulator’s approvals.

Latin America contributes about four per cent to Lupin’s global revenue and this is expected to double to around eight per cent over the next five years, said a senior company official. 

Martin Mercer, its president for Latin America, said the aim was to start exporting from Brazil next year. “We depend on manual packaging. We are now installing new equipment and working on augmenting the capacity. We plan to export to countries